Sodium–glucose co-transporter (SGLT)-2 inhibitors have shown consistent benefit in improving heart failure-related outcomes but not ischaemic cardiovascular events such as myocardial infarction or stroke. We assessed if the dual SGLT1/2 inhibitor sotagliflozin improves ischaemic outcomes.MethodsWe did a prespecified secondary analysis of the SCORED trial, which was a double-blind, placebo-controlled, randomised clinical trial enrolling patients (aged… Continue reading Effect of #sotagliflozin on major adverse cardiovascular events: a prespecified secondary analysis of the SCORED randomised trial
2 Medical News 